Browse > Article

Chemistry and Biology of Ras Farnesyltransferase  

Cho, Kwang-Nym (Bio-Organic Science Division, Korea Research Institute of Chemical Technology)
Lee, Kee-In (Bio-Organic Science Division, Korea Research Institute of Chemical Technology)
Publication Information
Archives of Pharmacal Research / v.25, no.6, 2002 , pp. 759-769 More about this Journal
Abstract
Mutated forms of ras are found in many human tumors and the rate of incidence is significantly higher in colon and pancreatic cancers. The protein product from the ras oncogene is a small G-protein, $p21^{ras}{\;}(Ras)$ that is known to playa key role in the signal transduction cascade and cell differentiation and proliferation. Mutated Ras is unable to regulate itself and remains constantly activated, leading to uncontrolled cell growth. The function of Ras in signal transduction requires its location near the growth factor receptor at the cell membrane. However, Ras does not have a transmembrane domain. Ras requires farnesylation to increase its hydrophobicity and subsequent plasma membrane association for its transforming activity. This key post-translational modification is catalyzed by the enzyme Ras farnesyltransferase (FTase), which transfers a farnesyl group from farnesylpyrophosphate to the C-terminal cysteine of the Ras protein. The requirement has focused attention on FTase as a target for therapeutic intervention. Selective inhibition of FTase will prevent Ras protein from association with the plasma membrane, leading to a disruption of oncogenic Ras function.
Keywords
ras Oncogene; Ras; Signal transduction cascade; Ras Farnesyltransferase; CAAX motif; Peptidomimetics;
Citations & Related Records

Times Cited By Web Of Science : 7  (Related Records In Web of Science)
Times Cited By SCOPUS : 7
연도 인용수 순위
1 Park, H.-W, Boduluri, S. R, Moornaw, J. F., Casey, P. J. and Beese, L. S., Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science, 275, 1800-1805 (1997)   DOI   PUBMED   ScienceOn
2 Cadena, D. L. and Gill, G. N., Receptor tyrosine kinases. FASEB J., 6, 2332-2337 (1992)   DOI   PUBMED
3 Bos, J. L., Ras Oncogenes in human cancer. Cancer Res., 49, 4682-4689 (1989)   PUBMED
4 Casey, P. J., Solski, P. A, Der, C. J. and Buss, J. E., p21 Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA, 86, 8323-8327 (1989)   DOI   ScienceOn
5 Cox, A D. and Der, C. J., Farnesyltransferase inhibitors and cancer treatment: Targetingsimply Ras?. Biochim. Biophy Acta., 1333, F51-F71(1997)
6 Barbacid, M., Ras gene. Annu. Rev. Biochem., 56, 779-827 (1987)   DOI   PUBMED   ScienceOn
7 Brown, M. S., Goldstein, J. L., Paris, K. J., Burnier, J. P. and Marsters, J. J., Tetrapeptide inhibitors of protein farnesyItransferase: Amino-terminal substitution in phenylalaninecontaining tetrapeptides restores farnesylation. Proc. Natl. Acad.Sci. USA, 89, 8313-8316 (1992)   DOI   ScienceOn
8 Casey, P. J., Biochemistry of protein prenylation. J. Lipid Res., 33, 1731-1740 (1992)   PUBMED
9 Dunten, P, Kammlott, U., Crowther, R., Weber, D., Palermo, R. and Birktoft, J., Protein farnesyltransferase: Structure and implications for substrate binding. Biochemistry, 37, 7907-7912 (1998)   DOI   ScienceOn
10 Gutierrez, L., Magee, A. I., Marshall, C. J. and Hancock, J. F, Post-translational processing of p21 ras is two-step and involves carboxyl-rnethylation and carboxyterminal proteolysis. EMBO J., 8, 1093-1098 (1989)   PUBMED
11 Hamilton, A D. and Sebti, S. M., Inhibitors of Ras farnesyltransferase as novel antitumor agents. Drug News Perspect., 8, 138-145 (1995)
12 Hunt, J. T, Lee, Y. G., Leftheris, K., Seizinger, B., Carboni, J., Mabus, J., Ricca, C., Yan, N. and Manne, V, Potent, cell active, non-thiol tetrapeptide inhibitors offarnesyltransferase. J. Med. Chem., 39, 353-358 (1996)   DOI   ScienceOn
13 McCormick, F., Ras GTPase activating protein: Signal transmitter and signalterminator. Cell, 56, 5-8 (1989)   DOI   PUBMED   ScienceOn
14 Lowy, D. R. and Willumsen, B. M., Function and regulation of Ras. Annu. Rev. Biochem.,62, 851-891 (1993)   DOI   ScienceOn
15 Maignan, S., Guilloteau, J.-P., Fromage, N., Arnoux, B., Becquart, J. and Ducruix, A, Crystal structure of the mammalian Grb2 adaptor. Science, 268, 291-293 (1995)   DOI   PUBMED
16 Masrers, J. C., Jr., McDowell, R. S., Reynilds, M. E, Oare, D. A., Somers, T. C., Stanley,M. S., Rawson, T. E., Struble, M. E., Burdick, D. J., Chan, K. S., Duarte, C. M., Paris, K. J., Tom, J. Y, Wan, D. T, Xue, Y and Burnier, J. P., Benzodiazepinepeptidomimetic inhibitors of farnesylferase. Bioorg. Med. Chem., 2, 949-957(1994)   DOI   ScienceOn
17 McCormick, F, How receptors turn Ras on. Nature, 363, 15-16 (1993)   DOI   PUBMED   ScienceOn
18 Mu, Y, Omer, C. A and Gibbs, R. A, On the stereochemical course of human protein farnesyltransferaes. J. Am. Chem. Soc., 118, 1817-1823(1996)   DOI   ScienceOn
19 Patel, D. V., Gordon, E. M., Schmidt, R. J., Weller, H. N., Young, M. G., Zahler, R, Barbacid, M., Carboni, J. M., GulloBrown, J. L., Huniham, L., Ricca, C., Robinson, S., Seizinger, B. R, Tuomari, A V and Mann, V, Phosphinyl acid-based bisubstrate analog inhibitors of Ras famesyl protein transferase. J. Med. Chem., 38, 435-442 (1995)   DOI   ScienceOn
20 Stricklanc, C. L., Windsor, W. T., Syto, R., Wang, L., Bond, R., Wu, Z. Schwartz, J., Le, H. V., Beese, L. S. and Weber, P. C., Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry, 37, 16601-16611(1998)   DOI   ScienceOn
21 Edelstein, R. L., Weller, V. A. and Distefano, M. D., Stereo chemical analysis of the reaction catalyzed by yeast protein famesyltransferase. J. Org. Chem., 63, 5298-5299 (1998)   DOI   ScienceOn
22 Weller, V. A and Distefano, M. D., Measurement of the $\alpha$-Secondary kinetic isotope effect for a prenyltransferase by MALDI mass spectrometry. J. Am. Chem. Soc., 120, 7975-7976 (1998)   DOI   ScienceOn
23 Moodie, S. A. and Wolfman, A., The 3Rs of life: Ras, Raf and Growth regulation. TlG,10, 44-48 (1994)
24 Hancock, J. F., Magee, A. I., Childs, J. E. and Marshall, C. J., All ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167-1177 (1989)   DOI   ScienceOn
25 Matthews, R. G. and Goulding, C. W., Enzyme-catalyzed methyl transfers to thiols: Therole of zinc. Curr. Opin. Chem. Biol., 1, 332-339(1997)   DOI   ScienceOn
26 Reiss, Y, Brown, M. S. and Goldstein, J. L., Divalent cation and prenyl pyrophosphate specificities of the protein famesyl transferase from rat brain, a zinc metalloenzyme. J. Biol. Chem., 267, 6403-6408 (1992)   PUBMED
27 Pai, E. F., Krengel, U., Gregoty, A. P., Goody, R. S., Kabsch, W. and Wittinghofer, A., Refiend crystal Structure of the triphosphate conformation of H-ras p21 at 1.35 Aresolution: Implications for the mechanism of GTP hydrolysis. EMBO J., 9, 2351-2359 (1990)   PUBMED
28 Leonard, D. M., Ras famesyltransferase: A new therapeutic target. J. Med. Chem., 40, 2971-2990 (1997)   DOI   PUBMED   ScienceOn
29 Dolence, J. M. and Poulter,C. D., A mechanism for posttranslationaI modifications of proteins by yeast protein farnesyltransferase. Proc. Natl. Acad. Sci. USA, 92, 5008-5011 (1995)   DOI   ScienceOn
30 Krengel, U., Schlichting, I., Scherer, A., Schumann, R., French, M., John, J., Kabsch, W, Pai, E. F. and Wittinghofer, A., Three-dimensional structures of H-ras p21mutants: Molecular basis for their inability to function as signal switch molecules. Cell, 62, 539-548 (1990)   DOI   ScienceOn
31 Casey, P. J. and Seabra, M. C., Protein prenyltransferases. J. Biol. Chem., 271, 5289-5292 (1996)   DOI   PUBMED
32 Clerc, F.-F., Guitton, J.-D., Fromage, N., Lelievre, Y., Duchesne, M., Tocque, B., JamesBurcouf, E., Commercon, A. and Becquart, J., Constrained analogues of kcvfm with improved inhibitory properties against farnesyltransferase. Bioorg. Med.Chem., 5, 1779-1784 (1995)   DOI   ScienceOn
33 Fearon, E. R, Human cancer syndromes. Science, 278, 1043-1050(1997)   DOI   PUBMED   ScienceOn
34 Hinterding, K., Alonso-Diaz, D. and Waldmann, H. Organic synthesis and biological signal transduction. Angew. Chem. Int. Ed. Engl., 37, 688-749 (1998)   DOI   ScienceOn
35 Kobran, K. S., Culberson, J. C., Desolms, S. J., Giuliani, E. A, Mosser, S. D., Omer, C.A., Pitzenberger, S. M. and Bogusky, M. J., NMR studies of novel inhibitors bound to farnesyl protein transferase. Protein Sci., 4, 681-688 (1995)   DOI   PUBMED   ScienceOn
36 Barinaga, M., From bench top to bedside. Science, 278, 1036-1039 (1997)   DOI   PUBMED   ScienceOn
37 Long, S. B. and Casey, P. J., Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry, 37, 9612-9618 (1998)   DOI   ScienceOn
38 Park, H.-W. and Beese, L. S., Protein farnesyltransferase. Curr. Opin. Struct. Biol., 7,873-880 (1997)   DOI   ScienceOn
39 Reiss, Y, Goldstein, J. L., Seabra, M. C., Casey, P. J. and Brovn, M. S., Inhibition of purified p21 ras farnesyl protein transfease by Cys-AAX tetrapeptide. Cell, 62, 81-88 (1990)   DOI   ScienceOn
40 Buss, J. E. and Marsters, J. C., Jr., Farnesyl transferase inhibitors: The successes andsurprises of new class of potential cancer chemotherapeutics. Chemistry & Biology, 2, 787-791 (1995)   DOI   ScienceOn
41 Willumsen, B. M., Christensen, A, Hubert, N. L., Papageorge, A. G. and Lowy, D. R., The p21 ras C-terminus is required for transformation and membrane association. Nature, 310, 583-586 (1984)   DOI   ScienceOn
42 Der, C. J. and Cox, A. D., Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. Cancer Cells, 3, 331-340 (1991)   PUBMED
43 Fu, H.-W., Beese, L. S. and Casey, P. J., Kinetic analysis of zinc ligand mutants of mammalian protein famesyltransferase. Biochemistry, 37, 4465-4472 (1998)   DOI   ScienceOn
44 Gibbs, J. B., Graham, S. L., Hartman, G. D., Koblan, K. S., Kohl, N. E., Omer, C. A. and Oliff, A, Farnesyltransferase inhibitors versus Ras inhibitors. Curr. Opin. Chem. Biol., 1, 197-203 (1997).   DOI   ScienceOn
45 McCormick, F., Raf: The holy grail of Ras biology? Trends Cell Biol., 1994, 4, 347-350(1994)   DOI   PUBMED   ScienceOn
46 Grand, R. J. A and Owen D., The biochemistry of ras p21. Biochem. J., 279, 609-631(1991)   DOI   PUBMED
47 Hightower, K. E., Huang, C.-c., Casey, P. J. and Fierke, C. A., H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate, Biochemistry, 31, 15555-15562 (1998)
48 Leonard, D. M., Shuler, K. R, Poulter, C. J., Eaton, S. R, Sawyer, T. K., Hodges, J. C., Su, T-Z., Scholten, J. D., Gowan, R C., Sebolt-Leopold, J. S. and Doherty, A. M., Structure-activity relationships of cysteine-locking pentapeptide derivatives that inhibit ras farnesyltransferase. J. Med. Chem., 40, 192-200 (1997)   DOI   ScienceOn
49 Pawson, T and Schlessinger, J., SH2 and SH3 domains. J. Curro Biol. 3, 434-442 (1993)   DOI   ScienceOn
50 Hightower, K. E. and Fierke, C. A., Zinc-catalyzed sulfur alkylation: Insights from protein farnesyltransferase., Curr. Opin. Chem. Biol., 3, 176-181 (1999)   DOI   ScienceOn
51 Bolton, G. L., Sebolt-Leopold, J. S. and Hodges, J. C., In Bristol, J. A(Ed.), Annual reports in Medicinal Chemistry. vol. 29, Academic Press, New York, pp165-174, (1994)
52 Burn, C. J., Guitton, J.-D., Baudoin, B., Lelievre, Y., Duchesne,M., Parker,F., Fromage, N. and Commercon, A,Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J. Med. Chem., 40, 1763-1767 (1997)   DOI   ScienceOn
53 Heldin, C.-H. and Westermark B., Signal transduction by the receptors for platelet-derived growth factor. J. Cell Sci., 96, 193-196 (1990)   PUBMED